Novo Nordisk A S (NVO) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: $3K to $45K traded
Big funds13F, quarter ended Sep 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about NVO filings

Are insiders buying or selling Novo Nordisk A/S (NVO) stock?

Neither. Novo Nordisk A/S (NVO) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded NVO recently?

Rep. Kevin Hern (R) sold $1K to $15K on Sep 10, 2026, disclosed 15 days later. Rep. Kevin Hern (R) sold $1K to $15K on Aug 31, 2026, disclosed 25 days later. Rep. Scott Scott Franklin (R) bought $1K to $15K on Aug 26, 2026, disclosed 22 days later. In total, 2 members disclosed 3 NVO trades with trade dates in the last 180 days, filed a median 22 days after trading.

How current is this NVO smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on NVO

Lean long1 source:
- Funds
Lean short1 source:
- Congress

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
Lean short1 buy · 2 salesCongress
Congress filings. Amounts are filing ranges, not prices, and filings can lag the trade.
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about NVO filings

Are insiders buying or selling Novo Nordisk A/S (NVO) stock?

Neither. Novo Nordisk A/S (NVO) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded NVO recently?

Rep. Kevin Hern (R) sold $1K to $15K on Sep 10, 2026, disclosed 15 days later. Rep. Kevin Hern (R) sold $1K to $15K on Aug 31, 2026, disclosed 25 days later. Rep. Scott Scott Franklin (R) bought $1K to $15K on Aug 26, 2026, disclosed 22 days later. In total, 2 members disclosed 3 NVO trades with trade dates in the last 180 days, filed a median 22 days after trading.

How current is this NVO smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Funds

What funds are doing

12 moves · 6 mo

Buys/Adds$527.9MSells/Trims$484.1M

Buys/Adds (3)

WC
Walleye Capital
Q3 2026 13F
$44.9M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
QR
Qube Research
Q3 2026 13F
$10.1M
added
JS
Jim Simons
Q3 2026 13F
$31.9M
added

5 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 5 moves

Other smart money signals

Activist stakes, short interest & more

3 items

SI
Short Interest ChangeModerate
short-volume tape softening: latest 28.0% fell 11.8pp vs 20d avg 39.8%
SI
Short Interest ChangeLight
short-volume tape softening: latest 43.1% fell 6.2pp vs 19d avg 49.3%
SI
Short Interest ChangeModerate
short-volume tape softening: latest 26.1% fell 11.0pp vs 20d avg 37.1%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 4, 2026

Earnings came in 9.9% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 4, 2026

Period ending

Sep 30, 2026

Earnings per share

$0.89+9.88% beat

$0.81 expected

Revenue

DKK 79.19B

Financial statements: Alpha Vantage

Next report

What the street expects next

Estimates as of Nov 10, 2026

EPS expected

$4.31

$4.26 to $4.36

Revenue expected

$79.28B

7 analysts

Last 30 days

2up0down

Analysts raising estimates

Estimate drift

0.06

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 4, 2026	$0.89est. $0.81	+9.88%beat	DKK 79.19BAlpha Vantage	+5.6%from DKK 74.98B
Jun 30, 2026Reported Aug 5, 2026	$0.96est. $0.82	+17.07%beat	DKK 78.49BAlpha Vantage	+2.1%from DKK 76.86B
Mar 31, 2026Reported May 6, 2026	$6.63est. $6.96	-4.74%miss	DKK 96.82BAlpha Vantage	+24.0%from DKK 78.09B
Dec 31, 2025Reported Feb 3, 2026	$6.04est. $5.90	+2.37%beat	DKK 79.14BAlpha Vantage	-7.6%from DKK 85.68B
Sep 30, 2025Reported Nov 5, 2025	$1.02est. $0.77	+32.47%beat	DKK 74.98BAlpha Vantage	+5.1%from DKK 71.31B
Jun 30, 2025Reported Aug 6, 2025	$5.96est. $6.00	-0.67%in line	DKK 76.86BAlpha Vantage	+12.9%from DKK 68.06B
Mar 31, 2025Reported May 7, 2025	$6.53est. $6.07	+7.58%beat	DKK 78.09BAlpha Vantage	+19.5%from DKK 65.35B
Dec 31, 2024Reported Feb 5, 2025	$6.34est. $5.97	+6.20%beat	DKK 85.68BAlpha Vantage	+30.1%from DKK 65.86B

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Prev close: $40.65
52-wk high: $61.11
52-wk low: $34.15
Mkt cap: $181.14B
P/E: 10.4x
ROE: +58.4%
Fwd P/E: 12.1x
Beta: 0.37
Div yield: 4.37%
P/S: 0.5x
P/B: 5.5x
Profit margin: +33.9%
Op margin: +50.8%

Fundamentals

Is the business strong?

Fairly priced and profitable.

Net margin: 33.9%
P/E: 10.38
Forward P/E: 12.09
Market cap: $181.1B

Valuation

P/S0.54
P/B5.53
Dividend yield4.4%

Quality

Operating margin50.8%
ROE58.4%
ROA19.1%

Growth

Beta0.37

Technicals

Price structure

This stock is trending upward.

Trend

Constructive

75 / 100

RSI 14

58balanced

20D volatility

32%annualized

52-week range

$40.65

$34.15$61.11

20D support

$37.96recent floor

20D resistance

$43.24recent ceiling

Returns

5D +0.9%20D +3.6%60D -12.5%

Price vs moving averages

SMA20 +2.1%SMA50 +1.1%SMA200 -4.6%

Volume pace

0.74xvs prior 20D

News

What the news says

21 articles · 7 days

Coverage leans bullish

9 bullish · 7 neutral · 5 bearish

Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady
NeutralNov 11
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
NeutralNov 10
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
Leans bearishNov 10
Industries affected by GLP-1 drugs: 10 winners and losers
BullishNov 10
FDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugs
BearishNov 9
Eli Lilly, Novo weight-loss drugs to get rare vision loss warning (LLY:NYSE)
BearishNov 9
US FDA orders new eye risk warnings for Ozempic, Zepbound
Leans bearishNov 9
Novo Nordisk Reports DKK 11.8 Billion in Share Buybacks
Leans bullishNov 9

33 macro signals shaping NVO right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

Novo Nordisk A/S

Smart money at a glance

What do analysts expect?

Questions about NVO filings

Smart money on NVO

Questions about NVO filings

What funds are doing

What Congress is doing

What fin-fluencers are saying

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 9.9% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Novo Nordisk A/S

Smart money at a glance

What do analysts expect?

Questions about NVO filings

Smart money on NVO

Questions about NVO filings

What funds are doing

What Congress is doing

What fin-fluencers are saying

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 9.9% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Novo Nordisk A/S

Overview

Questions about NVO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.

Novo Nordisk A/S

Overview

Questions about NVO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.